London, 23 June 2025

Keeping patients safe is at the heart of everything we do. We continuously collect and review data to monitor the safety of our products. This helps us identify and reduce risks early.

Our processes follow global standards to carefully monitor and assess any changes in the safety of our products. This helps us protect both patients and public health. Our Drug Safety Committee reviews safety concerns and promptly informs health authorities about any new risks. This structured approach shows our commitment to keeping our products safe and effective.

Every Hikma employee has an important role in keeping patients safe and must report any adverse events or safety concerns about our products to the pharmacovigilance team. This ensures that all safety reports undergo quick assessment and medical review. Moreover, when necessary, these reports are transmitted to the relevant regulatory authorities within the defined safety reporting timelines, ensuring compliance and upholding the highest standards of patient safety.